Published in Supportive Care in Cancer: Springer Journal analysis of the management of symptoms of depression among stage IV NSCLC 🫁 in Ontario, Canada 🇨🇦 link.springer.com/article/10.100… Alex Louie MD, PhD Natalie Coburn ICES #lungcancer #onctwitter #medtwitter

❗️ RTOG 0848 mOS 3.0 -> 3.9y with CRT 5-year OS 28.6% vs 48.1% CRT Stable tail effects > 5 years — more long term cured with CRT rather than chemo alone?! #asco24

Adriatic is the new Pacific as durva improves PFS and OS in LS-SCLC! So proud of my mentor Prof. Suresh Senan who lead this effort - lots to unpack here on PCI, RT schedule, and choice of platinum chemo #LCSM #RadOnc David Palma, MD, PhD Ben Slotman Shankar Siva Drew Moghanaki

Must read clinical trials in the field of #SBRT 2024 Please complement the list, to allow us staying up-to-date !

"Oligo"-no more! 🇨🇦ARREST phase I out now IJROBP - The Red Journal - Sue Yom ➡️SABR to median=16 "poly"metastases in patients who had already exhausted multiple lines of systemic therapy ➡️4x dose levels (up to 6Gyx5). ➡️No safety signals, QoL maintained. shorturl.at/gStwt Congrats! 👏👏

"What is 'too old' for spine SBRT re: risk of vertebral compression fracture (VCF)?" is something colleagues and I debated at tumor boards on many occasions. We now have the answer (OPEN access) IJROBP - The Red Journal Radiation Oncology arjun sahgal #radonc #SBRT sciencedirect.com/science/articl… 1/x

Should regional therapy be considered the preferred treatment approach in stage 2A/B seminoma? Read about our experience and approach Princess Margaret Cancer Centre IJROBP - The Red Journal Rob Hamilton Maria Jiang redjournal.org/article/S0360-…

Congrats to Rachel Glicksman and the team Radiation Medicine Program RMP Clinical Research Program Princess Margaret Cancer Centre for publishing this Ph2 single arm study of SBRT for OPD. 🔑1yr PFS 32%; median 4.7mo overall, different by histology 🔑1 patient had Gr3 tox; overall very well tolerated 🔑No significant decline in

We are looking forward to some wonderful webinars coming up this month, including our very own ISRS President Arjun Sahgal! Check out our most recent newsletter to register for both webinars with arjun sahgal and Alex Louie MD, PhD, and see what else the ISRS has coming up! 👇

📢 🚨#lungcancer peeps. Please consider Prof Andrea Bezjak from University of Toronto for your next IASLC president! A very deserving candidate and a great representative for #radonc!!! Laura Dawson #lcsm

SBRT + 💊 in oligomets: 🧍‍♂️2294 pts | 🫁, breast, prostate, colorectal ⚠️Grade 3+ AEs: 1.5% ✅ SBRT Safe with systemic tx! #SBRT #OligoCare #ESTRO25 EORTC ESTRO Ciro Franzese

In Journal of Clinical Oncology, our reflections on the timely ASCO TORS guideline Nancy Lee Nadeem Riaz 💡Encourage MR (r/o T4+ENE) & PET (r/o contra in N+) 💡Promote ND qual (min # nodes), ⬇️ bilat ND (morbid) 💡Caution re: ❌chemo 2/2 ENE degree & real-world use of frozens re margin status

❗️ Important work for SCLC 1-10 brain mets -> SRS mOS 10.2 m Only 22% of patients needed salvage WBRT Median 2 brain mets ascopubs.org/doi/10.1200/JC…

1/10 📢 Excited to share our new systematic review looking at risks and outcomes of definitive radiotherapy for patients with comorbid ILD and early-stage NSCLC! IJROBP - The Red Journal Melissa Sam Soon Alex Louie MD, PhD Houda Bahig, MD PhD David Palma, MD, PhD authors.elsevier.com/c/1lWCS1Hx52Ns…

It hit home as I returned to Sunnybrook Health Sciences Centre, where my own mother received cancer treatment with a message of HOPE to all who fight this disease. To help the more than 247,000 Canadians this year alone who will be diagnosed with cancer, I was proud to announce an ambitious plan to

New data from the randomized PEMBRO-RT study demonstrate when an ICI-mediated Abscopal effect is most likely to occur in patients with stage IV NSCLC. Ralph Weichselbaum Sean Pitroda, M.D. Amy L. Cummings, MD PhD doi.org/10.1038/s43018…

Nasser Altorki's team publishes new data investigating the role of preop SBRT for NSCLC. This time, reporting their institutional data comparing preop SBRT-IO vs Chemo-IO. The results demonstrate a significant association with improved RFS at 2 years with SBRT delivered BEFORE

☢️ Finally published the High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy for LS-SCLC. ✅OS 43.5 versus 22.5 mo, (HR 0.68, 95% CI 0.48–0.98, p = 0.037) No more acute or late onset toxicity. ✅ Would you now consider 60 Gy bid the new standard of care? #LCSM

Honored to support the very first World Radiotherapy Awareness Day today, September 7th! 🌍 By working together, we can ensure every person facing cancer has access to life-saving radiotherapy. #WorldRTDay Camden Clark MC 📚 Learn more: worldradiotherapy.org

That’s David Harpole at #WCLC25 pointing out that with 70% already accrued to the VALOR study, more than 120 participants have already completed their 5y follow-up period. #CSP2005